Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

MiR-155 at the heart of oncogenic pathways

Oncogene volume 33, pages 677–678 (2014)Cite this article

Subjects

Abstract

MicroRNAs are increasingly being recognized as oncogenes and tumor suppressors in cancer. MicroRNA-155 (miR-155) is an established oncomiR in breast cancer and regulates several pro-oncogenic pathways. In light of this, Chiang’s group has discovered a novel pathway regulated by miR-155. MiR-155 directly targets the VHL tumor suppressor and, by doing so, promotes the activity of HIF transcription factors and angiogenesis. This pathway appears to be particularly relevant in triple-negative breast cancer.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Kong W, He L, Richards EJ, Challa S, Xu C-X, Permuth-Wey J et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 2014; 33: 679–689.

    Article  CAS  Google Scholar 

  2. Chen J, Wang B-C, Tang J-H . Clinical significance of MicroRNA-155 expression in human breast cancer. J Surg Oncol 2012; 106: 260–266.

    Article  CAS  Google Scholar 

  3. Kong W, Yang H, He L, Zhao J-J, Coppola D, Dalton WS et al. MicroRNA-155 is regulated by the transforming growth factor B/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008; 28: 6773–6784.

    Article  CAS  Google Scholar 

  4. Jiang S, Zhang H-W, Lu M-H, He X-H, Gu H, Liu M-F et al. MicroRNA-155 functions as an oncomiR in breast cancer by targeting the Suppressor of Cytokine Signaling 1 gene. Cancer Res 2010; 70: 3119–3127.

    Article  CAS  Google Scholar 

  5. Jiang S, Zhang LF, Zhang HW, Hu S, Lu MH, Liang S et al. A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 2012; 31: 1985–1998.

    Article  CAS  Google Scholar 

  6. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 2010; 285: 17869–17879.

    Article  CAS  Google Scholar 

  7. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007; 104: 16170–16175.

    Article  CAS  Google Scholar 

  8. Bruning U, Cerone L, Neufeld Z, Fitzpatrick SF, Cheong A, Scholz CC et al. MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Mol Cell Biol 2011; 31: 4087–4096.

    Article  CAS  Google Scholar 

  9. Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ . Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biol Ther 2011; 12: 908–914.

    Article  CAS  Google Scholar 

  10. Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L et al. Tumor suppressor BRCA1 epigenetically controls oncogenic micro-RNA-155. Nat Med 2011; 17: 1275–1282.

    Article  CAS  Google Scholar 

  11. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747–752.

    Article  CAS  Google Scholar 

  12. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF et al. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61–70.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

MC-K is supported by NCI CA122346 and BLR&D VA Merit Award; XZ is supported by DoD: W81XWH-11-1-0118, Komen: KG110028 and ACS: RSG-12-268-01-CCG. We thank G Doerman for preparing the figures, and Dr M Daston for editorial assistance.

Author information

Authors and Affiliations

  1. Department of Cancer Biology, The Vontz Center for Molecular Studies, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    M F Czyzyk-Krzeska & X Zhang

  2. Department of Veterans Affairs, VA Research Service, Cincinnati, OH, USA

    M F Czyzyk-Krzeska

Authors
  1. M F Czyzyk-Krzeska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M F Czyzyk-Krzeska.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Czyzyk-Krzeska, M., Zhang, X. MiR-155 at the heart of oncogenic pathways. Oncogene 33, 677–678 (2014). https://doi.org/10.1038/onc.2013.26

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2013.26

This article is cited by

Search

Advanced search

Quick links